AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00030693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-B7.1 vaccine
Description: Given intratumorally
Study NCT00030693 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant fowlpox-TRICOM vaccine
Description: Given intratumorally
Study NCT00030693 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00030693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT03379077 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LTP Plus
Description: LTP Plus is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
Study NCT03379077 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LTP Plus
Description: LTP Plus is comprised of two components; Learning through play (LTP) and Cognitive Behavior Therapy (CBT). The LTP Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
Study NCT02419313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: incobotulinumtoxinA
Description: Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.
Study NCT02419313 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.
Study NCT05271539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis alone group
Description: The Lucentis alone group received 3 monthly intravitreal injections of lucentis alone or less than 3 injections if the central foveal thickness reached 250 microns
Study NCT05271539 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis dexamethasone group
Description: Lucentis dexamethasone group received intravitreal injections of combination of both lucentis and commercial dexamethasone. the second group received monthly intravitreal injections of the same dose of ranibizumab combined with 0.4 mg in 0.1 ml dexamethasone (Dexamethasone sodium phosphate, Amriya Pharmaceuticals, Cairo, Egypt) in a separate 1ml syringe with 27- gauge × ½ inch sterile injection needle, followed by 2 Intravitreal ranibizumab, 1 month apart (with dexamethasone if follow up OCT shows less than 10% improvement from baseline i.e., PRN). Treatment was stopped when CMT improved below 250 µ.
Study NCT03833596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: All 3 arms will receive Prednisone - 2 will be standard course treatment, 1 will be short course and rapidly-tapered
Study NCT03833596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: All 3 arms will receive Prednisone - 2 will be standard course treatment, 1 will be short course and rapidly-tapered
Study NCT03833596 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Exclusive Enteral Nutrition
Description: 2 arms will receive EEN, in concurrence with either regular-course or short course and rapidly-tapered CS.
Study NCT03308110 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PF-06650833
Description: Two formulations of PF-006650833
Study NCT01319682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous lidocaine injection
Description: Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
Study NCT01319682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous normal saline injection
Description: The patients in Group C (placebo control group) received normal saline intravenous injection
Study NCT02739789 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: tDCS
Study NCT02739789 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS
Study NCT01514539 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cross-sectional
Description: Monitoring two recently discovered appetite hormones called ghrelin and neuropeptide YY (PYY). This study evaluated whether fasting or postprandial ghrelin or PYY is different btween lactating and nonlactating postpartum women matched for age, body weight, and adiposity.
Study NCT04439448 — intervention group
Intervention type: RADIATION
Intervention: dual-energy X-ray absorptiometry (DEXA) scan
Description: Whole body dual-energy X-ray absorptiometry (DEXA) scan to assess lean and fat mass
Study NCT04439448 — intervention group
Intervention type: OTHER
Intervention: Carotid and branchial artery ultrasound
Description: Ultrasound to assess carotid plaque and brachial artery flow mediated dilation
Study NCT04439448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 2-hour oral glucose tolerace test
Description: Ingestion of 75g of glucose syrup with blood collection for glucose and insulin at time 0, 90min and 120min
Study NCT02219126 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Study NCT00695643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine
Description: 3 g per day
Study NCT00695643 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 g per day
Study NCT03899753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-Octyl Cyanoacrylate and Mesh
Description: 2-Octyl Cyanoacrylate and a mesh will be applied to final closure of wounds after undergoing a Total Shoulder Arthroplasty
Study NCT04439448 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Blood collection for measurement of circulating proteins (cytokines) and isolation of immune cells
Study NCT03899753 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-Octyl Cyanoacrylate
Description: Incisions will be closed with 2-Octyl Cyanoacrylate after undergoing a Total shoulder arthroplasty
Study NCT04404712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [11C]MK-3168
Description: One PET scan involving administration of PET ligand \[11C\]MK-3168
Study NCT02308748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dofetilide
Description: * 8 am: Placebo~* 12 pm (noon): 250 µg~* 5:30 pm: 250 µg
Study NCT02308748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mexiletine
Description: * 8 am: weight x 4 mg/kg~* 12 pm (noon): Same as at 8 am~* 5:30 pm: Same as at 8 am
Study NCT02308748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: * 9 am : 30 µg/min per kg (loading) for 60 minutes and 10 µg/min per kg (maintenance) for 30 minutes~* 2 pm: 55 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes~* 7:30 pm: 52 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes
Study NCT02308748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: * 9 am: 5.63 mg/h per kg (loading) for 1 hour and 0.26 mg/h per kg (maintenance for 30 minutes)~* 2 pm: 6.14 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)~* 7:30 pm: 2.23 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)
Study NCT02308748 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: • 7:30 pm: 330 µg/h per kg (loading) for 60 minutes and 61 µg/h per kg (maintenance) for 30 minutes
Study NCT02308748 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (#2 Gelcap or IV saline)
Study NCT03364751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IQOS
Description: Patients will switch from cigarette smoking to ad libitum IQOS use.
Study NCT03364751 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cigarette
Description: Patients will continue to smoke cigarettes ad libitum.
Study NCT04097457 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent training for disruptive behaviors manual (Bearss, Johnson, Handen, Butter, Lecavalier, Smith & Scahill, 2018)
Description: The intervention is a short term parent training program based on behavioral principles, which can be delivered by trained therapist. The manual includes eleven core sessions, home visit session, follow-up telephone booster sessions and seven supplemental sessions, designed to be delivered individually to parents in an outpatient setting.~The protocol will be administered to groups of 3-4 parents, with a quantitative pretest-post test design evaluated at five time points, including a follow up at one month post intervention. The protocol will be administered in various community and educational locations, such as schools and community centers
Study NCT01869010 — intervention group
Intervention type: OTHER
Intervention: Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls
Description: This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month
Study NCT02413580 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IGIV-C
Description: An IV dose of 2 g/kg of IGIV-C was administered over 2 consecutive days at a dose of 1 g/kg per day.
Study NCT01072461 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HAS Training
Description: Robotically measured and facilitated training of the hemiparetic hand and arm in isolation, in a three dimensional haptically rendered virtual environment.
Study NCT01072461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HAT training
Description: Robotically measured and facilitated training of the hemiparetic hand and arm as an integrated functional unit, in a three dimensional haptically rendered virtual environment
Study NCT01072461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bimanual Training
Description: Robotically measured and facilitated training of the hemiparetic hand and non-hemiparetic hand together, in a three dimensional haptically rendered virtual environment
Study NCT00850473 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Patient will have one imaging modality - a Positron Emitting Tomography CT which includes F-18 FDG and heparin/intralipid infusion and Contrast Dye.
Study NCT01994954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RHO
Description: Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.
Study NCT01268748 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional laparoscopic procedure
Description: Patients allocated to this group will undergo laparoscopic cholecystectomy using two 12 mm ports and two 5 mm ports
Study NCT01268748 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Experimental laparoscopic procedure
Description: Patients allocated to this group will undergo laparoscopic cholecystectomy using only a transumbilical SILS port
Study NCT02608983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agar H1CC2013
Description: Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2013 as part of normal diet for 28 days
Study NCT02608983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agar H1CC2012
Description: Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2012 as part of normal diet for 28 days
Study NCT02608983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: Following a 28-day washout one 250ml drink / day containing 8g of maltodextrin as part of normal diet for 28 days
Study NCT01533324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1 combined with Leucovorin
Description: S-1 capsules 80mg/m2/d BID one week on and one week off Leucovorin tablets 50mg/d BID one week on and one week off
Study NCT03820635 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Osteopontin (OPN)
Description: the serum level of Osteopontin (OPN) will be measured in the subject's blood sample
Study NCT01544842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1 % tacrolimus ointment
Description: applied topically to oral mucosa
Study NCT01544842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1 % triamcinolone paste
Description: applied topically to oral mucosa
Study NCT01544842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Orabase paste
Description: applied topically to oral mucosa
Study NCT02572583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liugan Shuangjie Heji
Study NCT02572583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Shufeng Jiedu Capsule
Study NCT02942108 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piezo surgery
Study NCT02572583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oseltamivir Phosphate Capsule
Study NCT02942108 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Study NCT00624156 — intervention group
Intervention type: BEHAVIORAL
Intervention: Writing Intervention
Description: Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
Study NCT00624156 — intervention group
Intervention type: BEHAVIORAL
Intervention: Writing Intervention
Description: Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities. The 20-minute writing task will be introduced as a time management intervention
Study NCT02515279 — intervention group
Intervention type: DRUG
Intervention: Peginterferon alfa-2a
Description: 180 micrograms subcutaneous weekly for 48 weeks.
Study NCT02515279 — intervention group
Intervention type: DRUG
Intervention: Ribavirin
Description: 1000-1600 mg day orally for 48 weeks.
Study NCT03532386 — intervention group
Intervention type: PROCEDURE
Intervention: ICSI
Description: ICSI for both couples
Study NCT02398461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rHIgM22
Description: Administered via IV infusion
Study NCT02398461 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01489995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A (migalastat)
Description: 150 mg migalastat HCl in the fasting state (reference arm)
Study NCT01895920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Study NCT01489995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B (migalastat)
Description: 150 mg migalastat HCl with simultaneous consumption of a glucose drink
Study NCT01489995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C (migalastat)
Description: 150 mg migalastat HCl 1 hour before consumption of a high fat meal
Study NCT00424814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kaletra (lopinavir/ritonavir)
Description: (200/50 mg x2)x 2/d= 2 pills twice daily
Study NCT00424814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)
Description: Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily
Study NCT01200056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg versus 40mg.
Description: 2 arms comparing atorvastatin 10mg daily for 6 months to atorvastatin 40mg daily for 6 months. The primary endpoint would be the 6 months VH-IVUS findings and clinical outcomes.
Study NCT02131896 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional arm-Mediterranean diet
Study NCT02131896 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines
Study NCT03567057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADS-5102, 274 mg
Description: Oral capsules
Study NCT01961791 — intervention group
Intervention type: PROCEDURE
Intervention: gastrectomy
Description: gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
Study NCT03339882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifemin
Description: Remifemin 0.2g po bid\*12 weeks at the beginning of the LHRH-a treatment
Study NCT01489995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D (migalastat)
Description: 150 mg migalastat HCl 1 hour before consumption of a light meal
Study NCT01489995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E (migalastat)
Description: 150 mg migalastat HCl 1 hour after consumption of a light meal
Study NCT02557152 — intervention group
Intervention type: DEVICE
Intervention: GentleWave System Treatment
Study NCT03178266 — intervention group
Intervention type: DEVICE
Intervention: Knee Arthroplasty
Description: Standard Knee Arthroplasty will be performed on study subjects. The closure method will be studied at 3 weeks and 6 weeks and patients will be asked about satisfaction with the closure method assigned.
Study NCT03756428 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep dry needling in tibialis posterior
Description: The inspector, with gloves, disinfects the area to be treated with 70º alcohol. Once the alcohol is applied, the intervenor locates and takes the myofascial trigger point and places the needle with the guide tube resting on the skin of the patient. The inspector holds the guide tube between the index and middle fingers lightly touch the needle with the index finger of the other hand to insert the needle perpendicularly into the skin, directing it towards the inspector's thumb. Once the needle is inserted subcutaneously, the guide tube is removed. The controller deepens the needle to myofascial trigger point, and makes fast inputs and outputs into it. The rapid exit is made to the subcutaneous cellular tissue, outside the muscle, but not outside the skin. Next, hemostasis is performed in the area. Once this hemostasis is completed, the patient is incorporated and dressed.
Study NCT03756428 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham technique in tibialis posterior
Description: The patient lies on the stretcher without the trousers. The interventor, with the guide tube, simulates the technique of puncture in the right twin of the subject. The comptroller cleans the area with 70º alcohol. Once the alcohol is applied, he performs the simulated dry needling technique in a plane with his index and middle fingers with the guide tube. It is important that the subject has his head stuck in the hollow of the head of the stretcher throughout the technique to make a correct masking.
Study NCT04345978 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Fasting hours
Description: Normal Fasting hours before CRC surgery for 8 hours and feeding 8 hours after surgery; Prolong fasting hours before CRC surgery for 24 hours and feeding 24 hours after surgery.
Study NCT04345978 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting hours
Description: Normal Fasting hours before CRC surgery for 8 hours and feeding 8 hours after surgery; Prolong fasting hours before CRC surgery for 24 hours and feeding 24 hours after surgery.
Study NCT01641744 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Systematic Training for Effective Parenting (STEP)
Description: Parenting skills training class, 1x/week, 12 weeks
Study NCT01641744 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Attachment Based Intervention (GABI)
Description: Parent-child group, 3x/week, 26 weeks
Study NCT01056757 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000 mg bid, po, q28days